Novartis AG · SIX:NOVN
Novartis — Investor Day (January 2004)
9 slides from Novartis's investor day presentation, Jan 22, 2004
Slide 1: Consumer Health: Dynamic Growth and Margin Expansion
Consumer Health Dynamic Growth and Margin Expansion Paul Choffat Head of Novartis Consumer Health and Member of the Executive Committee Agenda • Division performance in 2003 • Business Unit highlights 2003 • 2004 priorities 2 FRESCO 2003 / Paul Choffat / 2004-01-22 / Analysts 1
Slide 2: Strong Performance of Consumer Health in 2003
Strong Performance of Consumer Health in 2003 • Market share gains across all Business Units • Strong performance led by Sandoz and OTC • Successful product launches/roll-outs across all Business Units, especially in US • Sales growth of +24% vs. 2002 in USD (+16% in LC) reaching USD 8.8 bn • Operat
Slide 3: Dynamic Growth of Medicines Businesses
Dynamic Growth of Medicines Businesses 3rd party sales 2003 Sales split by BU LC growth USD m vs 2002 CV Sandoz Sandoz 2 906 +47% 15% OTC 1 772 +7% 33% Animal Health 682 +3% 1 I&B 15% Medical Nutrition 815 +9% Infant & Baby 1 361 +3% CIBA Vision 1 308 +7% MN 9% 8% 20% Total Division 8 844 +16% AH OT
Slide 4: OTC Highlights 2003
Agenda • Division performance in 2003 • Business Unit highlights 2003 • 2004 priorities 7 FRESCO 2003 / Paul Choffat / 2004-01-22 / Analysts OTC Highlights 2003 • 5 global strategic brands with a combined growth rate of 13% Voltaren® Lamisil® Nicotinell® Calcium- Otrivin® Sandoz® • Successful launch
Slide 5: OTC Sales Force Rated As #1 Across All Metrics
OTC Sales Force Rated As #1 Across All Metrics OTC Mirror survey among 3 700 pharmacists in 13 European countries Sales Force metric Novartis rank Help grow sales #1 Expertise #1 Prompt delivery #1 Continuity #1 Trustworthy #1 Effective use of time #1 Communication skills #1 9 FRESCO 2003 / Paul Cho
Slide 6: Success of Deramaxx in US
Success of Deramaxx® in US • First COX II inhibitor to enter USD 100 m US canine pain market, dominated by Pfizer and Fort Dodge • Rapid uptake in the market – Category growth of +47% vs 2002 – Deramaxx achieves 21% market segment share against fierce competition and two new entrants (Merial, Scheri
Slide 7: Mead Johnson: Strengthening Our Global #2 Position
Mead Johnson: Strengthening Our Global #2 Position • 2002 sales of USD 223 m • Access to the fast-growing, higher margin US retail channel • Enter Japan • Leverage our disease-specific product portfolio % US Medical Nutrition market segment share, 1H 2003 Others Tyco 13% 4% Nestlé 6% 49% Abbott Mead
Slide 8: Feeding Infants & Toddlers Study (FITS)
Feeding Infants & Toddlers Study (FITS) Illustrates Importance of Early Nutrition • Dietary intake study revealed many children consume too many calories and inappropriate food, leading to childhood obesity • FITS reached experts audience and 46 m consumers • Gerber recognized as industry thought le
Slide 9: 2004 Consumer Health Priorities
Agenda • Division performance in 2003 • Business Unit highlights 2003 • 2004 priorities 17 FRESCO 2003 / Paul Choffat / 2004-01-22 / Analysts 2004 Consumer Health Priorities • Sales growth outpacing the market in all Business Units, and Operating Income growing even faster • Continue to focus on str